Table 1 Comparison of clinical characteristics and antimicrobial susceptibility patterns between hvKP and cKP isolates
Clinical characteristic | hvKP (n = 4) | cKP (n = 57) | P value |
|---|---|---|---|
Basic demographics | |||
Age | 52.25 ± 4.46 | 42.72 ± 1.715 | 0.154 |
Male | 2 (50.0%) | 18 (31.6%) | 0.835 |
WBC (0) | 4 (100.0%) | 57 (100.0%) | - |
Nitrite (negative) | 4 (100.0%) | 57 (100.0%) | - |
Antimicrobial susceptibility [n (S, %)] | |||
Ceftazidime | 4 (100.0%) | 53 (93.0%) | 1.000 |
Cefepime | 4 (100.0%) | 52 (91.2%) | 1.000 |
Imipenem | 4 (100.0%) | 57 (100.0%) | - |
Meropenem | 4 (100.0%) | 57 (100.0%) | - |
Ceftazidime / avibactam | 4 (100.0%) | 57 (100.0%) | - |
Aztreonam | 4 (100.0%) | 52 (91.2%) | 1.000 |
Piperacillin / tazobactam | 4 (100.0%) | 57 (100.0%) | - |
Nitrofurantoin | 2 (50.0%) | 46 (80.7%) | 0.196 |
Amikacin | 4 (100.0%) | 57 (100.0%) | - |
Levofloxacin | 4 (100.0%) | 53 (93.0%) | 1.000 |
Tigecycline | 4 (100.0%) | 57 (100.0%) | - |
Polymyxin | 4 (100.0%) | 56 (98.2%) | 1.000 |